STA Pharmaceutical – a subsidiary of WuXi AppTec – has announced that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the US Food and Drug Administration (FDA) within the same week, with no Form 483s issued. This marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture; it also shows a commitment to providing integrated R&D and manufacturing services with the highest quality standard for customers.
This shows a commitment to providing integrated R&D and manufacturing services with the highest quality standard for customers
"It's a point of great pride that our quality systems allow us to be inspected at short notice by any applicable regulatory agency in the world. In this case, we received two separate inspection notices from FDA only seven days and five days in advance of the inspections, respectively. It's an endorsement of the real-time monitoring and quality culture we run across all parts of the company," commented Ms Mei Hao, Vice President of Quality at WuXi STA. "It's another key example of the rigorous nature of our global standard quality systems. It is also another milestone for our platform, and in our efforts to have geographically integrated capabilities for both drug product and drug substance."
WuXi STA has now successfully passed seven inspections from the US FDA since 2013, producing branded drugs marketed in 95 countries. Its Analytical Service Unit provides clients with a full spectrum of analytical method development, validation and testing services from preclinical to commercial. The Changzhou facility with over 1,700,000 square feet has established a variety of new technology platforms such as spray dried dispersion, continuous processing (flow chemistry), oligonucleotides and peptides. It successfully completed the first US FDA inspection in 2018.
